Insulet Co. (NASDAQ:PODD) Shares Sold by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC lessened its position in shares of Insulet Co. (NASDAQ:PODD) by 6.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 75,982 shares of the medical instruments supplier’s stock after selling 4,810 shares during the quarter. Stephens Investment Management Group LLC’s holdings in Insulet were worth $19,837,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in PODD. Baillie Gifford & Co. increased its holdings in Insulet by 20.7% during the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock valued at $529,669,000 after acquiring an additional 389,639 shares in the last quarter. Mizuho Securities USA LLC grew its position in shares of Insulet by 5,928.1% in the third quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier’s stock valued at $75,835,000 after purchasing an additional 320,416 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Insulet by 43.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after purchasing an additional 193,839 shares in the last quarter. Westfield Capital Management Co. LP raised its position in shares of Insulet by 27.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after purchasing an additional 163,388 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec purchased a new stake in Insulet in the 3rd quarter valued at approximately $16,342,000.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on PODD. Sanford C. Bernstein started coverage on Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target for the company. Citigroup lifted their price objective on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Canaccord Genuity Group upped their target price on shares of Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a report on Monday, December 9th. JPMorgan Chase & Co. lifted their price target on shares of Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a report on Thursday, December 12th. Finally, Morgan Stanley upped their price objective on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $277.13.

Insulet Price Performance

PODD stock opened at $283.08 on Monday. The company has a market cap of $19.86 billion, a PE ratio of 48.47, a price-to-earnings-growth ratio of 3.61 and a beta of 1.23. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The stock has a 50-day moving average price of $270.27 and a two-hundred day moving average price of $241.58. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $289.46.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.13. Insulet had a return on equity of 27.98% and a net margin of 21.22%. The business had revenue of $543.90 million during the quarter, compared to analysts’ expectations of $518.50 million. During the same quarter in the previous year, the business earned $0.71 EPS. As a group, research analysts predict that Insulet Co. will post 3.22 EPS for the current year.

Insider Buying and Selling at Insulet

In other news, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by corporate insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.